Systems for attaining a predetermined porosity of a vascular device

Information

  • Patent Grant
  • 9907643
  • Patent Number
    9,907,643
  • Date Filed
    Monday, August 24, 2015
    8 years ago
  • Date Issued
    Tuesday, March 6, 2018
    6 years ago
Abstract
A system for treating a patient is provided that includes an expandable vascular device having a body having a substantially uniform porosity that is adapted to change by adjusting an axial length of the body. The system also includes an expanding member positioned within a central lumen of the device, the expanding member configured to engage the body, as the body is radially expanded from a collapsed configuration, and to reduce a porosity of the body within a body region more than the body porosity is reduced outside the region.
Description
BACKGROUND

Lumens in a patient's body can change in size, shape, and/or patency, and such changes can present complications or affect associated bodily functions. For example, the walls of the vasculature, particularly arterial walls, may develop a pathological dilatation, commonly called an aneurysm. Aneurysms are observed as a ballooning-out of the wall of an artery. This is a result of the vessel wall being weakened by disease, injury, or a congenital abnormality. Aneurysms have thin, weak walls and have a tendency to rupture and are often caused or made worse by high blood pressure. Aneurysms can be found in different parts of the body; the most common being abdominal aortic aneurysms (AAA) and the brain or cerebral aneurysms. The mere presence of an aneurysm is not always life-threatening, but an aneurysm can have serious health consequences such as a stroke if one should rupture in the brain. Additionally, a ruptured aneurysm can also result in death.


SUMMARY

The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples, and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause, e.g., clause 1, 16 and 23. The other clauses can be presented in a similar manner.


1. A system for treating a patient, the system comprising:

    • an expandable vascular device comprising a body having a substantially uniform porosity that is adapted to change by adjusting an axial length of the body, and
    • an expanding member positioned within a central lumen of the device, the expanding member configured to engage the body, as the body is radially expanded from a collapsed configuration, and to reduce a porosity of the body within a body region more than the body porosity is reduced outside the region.


2. The system of clause 1, wherein the body comprises a braided structure.


3. The system of clause 1, wherein the body comprises a cut metal tube.


4. The system of clause 1, wherein the body comprises a self-expanding structure.


5. The system of clause 1, wherein an axial length of the expanding member in the collapsed configuration is about 200-500% longer than the axial length of the expanding member in an expanded configuration.


6. The system of clause 5, wherein a change in the axial length of the expanding member from the collapsed configuration to the expanded configuration is the same as a change in the axial length of the body from a body collapsed configuration to a body expanded configuration.


7. The system of clause 1, further comprising an adhesive disposed between the expanding member and the region for adhering a portion of the region to the expanding member.


8. The system of clause 7, wherein the adhesive comprises biodegradable material.


9. The system of clause 1, further comprising a corrugated tube disposed within the expanding member, the corrugated tube configured to axially shorten as the expanding member is inflated.


10. The system of clause 1, wherein the expanding member comprises, when expanded, an enlarged region having an enlarged diameter relative to other regions of the expanding member, the enlarged region being substantially axially aligned with the body region.


11. The system of clause 10, further comprising an adhesive disposed between the enlarged region of the expanding member and the body region.


12. The system of clause 1, wherein the expanding member comprises, when expanded, a reduced region having a reduced diameter relative to other regions of the expanding member, the reduced region being substantially axially aligned with the body region.


13. The system of clause 12, further comprising an adhesive disposed proximally or distally of the reduced region of the expanding member.


14. The system of clause 1, wherein the expanding member comprises, when expanded, two enlarged regions having an enlarged diameter relative to a reduced region therebetween, having a reduced diameter, the reduced region being substantially axially aligned with the body region.


15. The system of clause 14, further comprising an adhesive disposed between the enlarged regions and the body.


16. A delivery system for a vascular device, the delivery system comprising:

    • a catheter having a lumen;
    • a guide wire extending through the catheter lumen;
    • a vascular device having a porosity that is altered by adjustment of an axial length of the device; and
    • an expanding member disposed within a distal portion of the catheter, the expanding member configured to axially shorten as the expanding member is radially expanded;
    • wherein the expanding member is configured to engage a region of the device and reduce, as the expanding member axially shortens, a porosity of the device within the region more than the porosity is reduced outside the region.


17. The system of clause 16, wherein an axial length of the expanding member in a collapsed configuration is about 200-500% longer than the axial length of the expanding member in a radially expanded configuration.


18. The system of clause 17, wherein a change in the axial length of the expanding member from the collapsed configuration to the radially expanded configuration is the same as a change in the axial length of the device from a device collapsed configuration to a device expanded configuration.


19. The system of clause 16, further comprising an adhesive disposed between the expanding member and the region for adhering a portion of the region to the expanding member.


20. The system of clause 16, wherein the expanding member comprises, when radially expanded, an enlarged region having an enlarged diameter relative to other regions of the expanding member, the enlarged region being substantially axially aligned with the region of the device.


21. The system of clause 16, wherein the expanding member comprises, when radially expanded, a reduced region having a reduced diameter relative to other regions of the expanding member, the reduced region being substantially axially aligned with the region of the device.


22. The system of clause 16, wherein the expanding member comprises, when radially expanded, two enlarged regions having an enlarged diameter relative to a reduced region therebetween, having a reduced diameter, the reduced region being substantially axially aligned with the region of the device.


It is understood that other configurations of the subject technology will become readily apparent to those skilled in the art from the following detailed description, wherein various configurations of the subject technology are shown and described by way of illustration. As will be realized, the subject technology is capable of other and different configurations and its several details are capable of modification in various other respects, all without departing from the scope of the subject technology. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not as restrictive.





BRIEF DESCRIPTION OF THE DRAWINGS

A detailed description will be made with reference to the accompanying drawings:



FIG. 1A depicts a system for controllably deploying a vascular device in a collapsed configuration, according to some embodiments of the subject technology.



FIG. 1B depicts a system for controllably deploying a vascular device in an intermediate configuration, according to some embodiments of the subject technology.



FIG. 1C depicts a system for controllably deploying a vascular device in an expanded configuration, according to some embodiments of the subject technology.



FIG. 2 depicts a vascular device, according to some embodiments of the subject technology.



FIG. 3A depicts a parison used for manufacturing an expanding member, according to some embodiments of the subject technology.



FIG. 3B depicts an example process for manufacturing an expanding member, according to some embodiments of the subject technology.



FIG. 3C depicts an example process for manufacturing an expanding member, according to some embodiments of the subject technology.



FIG. 3D depicts an expanding member, according to some embodiments of the subject technology.



FIG. 3E depicts an expanding member, according to some embodiments of the subject technology.



FIG. 4A depicts a vascular device coupled to an expanding member using an adhesive, according to some embodiments of the subject technology.



FIG. 4B depicts a vascular device coupled to an expanding member using an adhesive, according to some embodiments of the subject technology.



FIG. 4C depicts a vascular device coupled to an expanding member using an adhesive, according to some embodiments of the subject technology.



FIG. 4D depicts a vascular device coupled to an expanded expanding member using an adhesive, according to some embodiments of the subject technology.



FIG. 5A depicts an expanding member having an enlarged region, according to some embodiments of the subject technology.



FIG. 5B depicts an expanding member having an enlarged region disposed within a vessel, according to some embodiments of the subject technology.



FIG. 6A depicts an expanding member having a reduced region, according to some embodiments of the subject technology.



FIG. 6B depicts an expanding member having a reduced region disposed within a vessel, according to some embodiments of the subject technology.



FIG. 7A depicts an expanding member having two enlarged regions, according to some embodiments of the subject technology.



FIG. 7B depicts an expanding member having two enlarged regions disposed within a vessel, according to some embodiments of the subject technology.



FIG. 8A depicts an example of a catheter, according to some embodiments of the subject technology.



FIG. 8B depicts another example of a catheter, according to some embodiments of the subject technology.



FIG. 9 depicts a cross section view of a vessel and delivery of a vascular device according to some embodiments of the subject technology.



FIG. 10 depicts a cross section view of a vessel and delivery of a vascular device according to some embodiments of the subject technology.



FIG. 11 depicts a cross section view of a vessel and delivery of a vascular device according to some embodiments of the subject technology.



FIG. 12 depicts a cross section view of a vessel and delivery of a vascular device according to some embodiments of the subject technology.



FIG. 13 depicts a cross section view of a vessel and delivery of a vascular device according to some embodiments of the subject technology.



FIG. 14 depicts a cross section view of a vessel and a vascular device according to some embodiments of the subject technology.





DETAILED DESCRIPTION

The detailed description set forth below is intended as a description of various configurations of the subject technology and is not intended to represent the only configurations in which the subject technology may be practiced. The appended drawings are incorporated herein and constitute a part of the detailed description. The detailed description includes specific details for the purpose of providing a thorough understanding of the subject technology. However, it will be apparent to those skilled in the art that the subject technology may be practiced without these specific details. In some instances, well-known structures and components are shown in block diagram form in order to avoid obscuring the concepts of the subject technology.


Aneurysms may be located, for example, along vessel side walls. A neck of an aneurysm typically defines an opening of between about 2 to 25 mm, though other sizes and ranges are also possible. The neck connects an anatomical lumen to a fundus of the aneurysm. In some embodiments, “vessel” or “lumen” may refer to blood vessels (including arteries and veins) or other suitable body organs having a lumen, such as the gastrointestinal tract (e.g., esophagus, stomach, small intestine, colon, rectum), bile ducts, urinary bladder, ureter, urethra, trachea, bronchi, and the like. Blood flow within the anatomical lumen flows through the neck and into the fundus. In response to the constant blood flow into the fundus of the aneurysm, the wall of the aneurysm continues to distend and presents a significant risk of rupturing. When the blood within the aneurysm causes pressure against the wall of the aneurysm that exceeds the wall strength, the aneurysm ruptures.


Reduction of blood flow to or within the aneurysm results in a reduction in force against the wall of the aneurysm and a corresponding reduction in the risk of rupturing. A reduction of the force and volume of blood entering the aneurysm may be accomplished by an occluding device. Occluding devices may be dependent on a physician's skill during deployment, to ensure that a desired porosity is attained at the neck of the aneurysm. If the porosity too high at the neck, then the occluding device may fail in sufficiently reducing the blood flow into the fundus. The porosity of some occluding devices may be reduced by applying a longitudinally compressive force to a proximal portion of the occluding device towards the direction of a distal portion. Because the porosity of the occluding device may be modified by application of the compressive force, achieving the desired porosity consistently and reliably is heavily dependant on physician skill.


The methods and systems of the subject technology solve some or all of the foregoing problems by controlling the deployment of a vascular device such that the device occludes blood flow into the aneurysm consistently and reliably, to thereby prevent or reduce likelihood of aneurysm ruptures. The system includes an expandable vascular device and an expanding member positioned within a central lumen of the vascular device. The expanding member is configured to attain a predetermined porosity for a region of the device during deployment. Accordingly, controlling the deployment of the vascular device using the expanding member to attain the predetermined porosity for the region, reduces or stops the laminar flow into the aneurysm, thereby allowing the blood within the aneurysm to begin to stagnate. Stagnation of blood, as opposed to continuous flow through a fundus of the aneurysm, results in thrombosis in the aneurysm, which also helps protect the aneurysm from rupturing.



FIGS. 1A-1C depict a system 100 for controllably deploying a vascular device 110, according to some embodiments of the subject technology. The system 100 includes an expandable vascular device 110, an expanding member 120 positioned within a central lumen of the vascular device 110, and a catheter 130.


Referring to FIG. 2, the vascular device 110 comprises a body 111 having a substantially uniform porosity. The body 111 may be formed of a plurality of substantially uniformly spaced members 112. The porosity of the body 111 is adapted to change by adjusting an axial length of the body 111. For example, the body 111 may be configured to decrease in porosity as a result of being axially shortened during and/or after diametrical, or radial, expansion. The body 111 may be a self-expanding stent made of two or more round or ovoid wire filaments 112. Accordingly, the body 111 has a first, collapsed configuration, and a second, expanded configuration. The filaments 112 may be formed of known flexible materials including shape memory materials, such as nitinol, platinum and stainless steel. The body 111 may be fabricated from platinum/8% tungsten and 35N LT (cobalt nickel alloy, which is a low titanium version of MP35N alloy) alloy wires. In other embodiments, one or more of the filaments 112 can be formed of a biocompatible metal material or a biocompatible polymer. The filaments 112 may be braided into a resulting lattice-like structure. In at least one embodiment, during braiding or winding of the body 111, the filaments 112 may be loosely braided using a 1-over-2-under-2 system. In other embodiments, however, other methods of braiding may be followed, without departing from the scope of the disclosure.


Alternatively, the body 111 may be formed, for example, by laser cutting a pre-formed tube or sheet, by interconnecting a multitude of members 112 by laser welding, or by other suitable methods such as electrochemical etching, grinding, piercing, electroforming, or other means. In another example, the body 111 may comprise a tubular stent.


The body 111 has a porosity configured to reduce haemodynamic flow into, for example, an aneurysm. The porosity of the body 111, determined by the plurality of members 112, may be adjusted by axially shortening the body 111. The ends of the body 111 may be cut to length and therefore remain free for radial expansion and contraction. The body 111 may exhibit a high degree of flexibility due to the materials used, the porosity of the body 111, and the fact that the ends are not secured.


Referring to FIGS. 1A-1C, the expanding member 120 is configured to engage the body 111 of the vascular device 110, as the body 111 is expanded from the first, collapsed configuration. The expanding member 120 may comprise an elastomeric balloon capable of being very elastic, such that an axial length of the expanding member 120 in a collapsed configuration is about 200-500% longer than the axial length of the expanding member 120 in an expanded configuration. The expanding member 120 may be formed from polyurethane, silicone, or other similar materials.


The expanding member 120 is configured to geometrically deform in a similar manner as the vascular device 110, as the body 111 moves from the first, collapsed configuration to the second, expanded configuration. For example, during expansion of the expanding member 120 from the collapsed configuration to the expanded configuration, the expanding member 120 may be configured to shorten in axial length and increase in radial dimension, or diameter, by the same amounts as the body 111 does when the body 111 moves from the first, collapsed configuration to the second, expanded configuration. In other words, a change in the axial length and radial dimension of the expanding member 120 from the collapsed configuration to the expanded configuration is the same as a change in the axial length and radial dimension of the body 111 from the first, collapsed configuration to the second, expanded configuration.


The expanding member 120 may have an inner member 125 disposed within a central longitudinal axis of the expanding member 120 that is configured to axially shorten during expansion or inflation of the expanding member 120. The inner member 125 may be configured to axially shorten by the same amount as the expanding member 120 axially shortens during expansion or inflation. The inner member 125 may, for example, comprise a corrugated tube, telescoping tube, or other structure configured to axially shorten or collapse. A proximal and distal end of the expanding member 120 may be attached, coupled, or adhered to a proximal and distal portion of the inner member 125.


In some aspects, to reduce the tendency of the expanding member 120 to creep or stress relax, the material of the expanding member 120 may be cross-linked. Cross-links are bonds, bi-functional polymer chains or multi-functional polymer chains that link one polymer chain of the expanding member 120 material to another. Cross-links can be formed by chemical reactions that are initiated by heat, pressure, change in pH, radiation, or other means. For example, mixing of an unpolymerized or partially polymerized resin with specific chemicals called cross-linking reagents results in a chemical reaction that forms cross-links between the polymer chains of the expanding member 120 material. If further protection from creep or stress relaxation is desired, the expanding member 120 could be shipped in an axially shortened and radially expanded configuration, or in the expanded configuration. In this example, the expanding member 120 may be configured to be “at rest” when the expanding member 120 is at its largest diameter and its shortest length.


Referring to FIGS. 3A-3D, the expanding member 120 may be manufactured using molds 310. In this process, a length of polymer tubing (parison) 320 is placed into the mold. Heater elements bring the parison to the working temperature and the parison is then axially stretched and internally pressurized “P” to form the expanding member 120. Using this process, the expanding member 120 may have varying cross sectional shapes either along the expanding member 120 length or normal to the expanding member 120 longitudinal axis, or both. This expanding member 120 manufacturing process may impart axial or biaxial orientation to the polymer chains of which the expanding member 120 may be comprised.


Alternatively, the expanding member 120 may be manufactured by solution casting. Solution casting is a process in which the mold is rotated, causing a solution in the mold to conform to the interior surface of the mold due to centrifugal force. After the solution has cured into a film, the mold is disassembled, thereby releasing the expanding member 120.


Other known methods may also be used to manufacture the expanding member 120. In some examples the expanding member 120 is comprised of wound or braided filaments imbedded in the elastomeric polymer. In another example the expanding member 120 may be comprised of braided filaments which can be axially lengthened or shortened using a telescoping rod and tube, the rod being attached to distal ends of the braided filaments and the tube being attached to proximal ends of the braided filaments.


The expanding member 120 may have a proximal cuff 122A and a distal cuff 122B for attachment to a catheter 130. In another embodiment, the expanding member 120 may only have a proximal cuff 122A, as shown in FIG. 3E. This embodiment is particularly useful for attaching to a distal end of a fixed wire catheter, as discussed further below.



FIGS. 4A-7B depict the vascular device 110 and the expanding member 120, according to some embodiments of the subject technology. The expanding member 120 is positioned within the central lumen of the vascular device 110 before and during deployment of the vascular device 110 within a patient's vasculature. The expanding member 120 may be configured to controllably expand the vascular device 110 such that the vascular device 110 attains a predetermined porosity at a particular region, such as near a treatment site which may be near a neck of an aneurysm. For example, during deployment, the expanding member 120 may cause a reduction in a porosity of the body 111 within a region 115A-D that is more than the reduction of the porosity of the body 111 outside the region 115A-D, thereby attaining a predetermined porosity for the region 115A-D.


Alternatively, the expanding member 120 may be configured to controllably expand the vascular device 110 such that the vascular device 110 attains a predetermined porosity in more than one region, such as proximal and distal to the neck of the aneurysm where pressure may be higher.


Referring to FIGS. 4A-4D, the expanding member 120 may controllably expand the vascular device 110 and attain the predetermined porosity for the region 115A by positively engaging a portion of the vascular device 110 before and during deployment. For example, an adhesive 117 may be used to positively engage, couple, attach, or adhere a portion of the vascular device 110 to an outer surface of the expanding member 120. The adhesive 117 assists in utilizing the axial shrinkage and radial expansion characteristics of the expanding member 120 to control the porosity of the vascular device 110 by positively engaging, coupling, attaching, or adhering the expanding member 120 to the vascular device 110.


The adhesive 117 may comprise biodegradable materials, or materials that dissolve in the body or in the bloodstream. For example, the adhesive 117 may include sugar, carbowax, polyethylene oxide, poly vinyl alcohol, poly lactic acid (PLA), poly glycolic acid (PGA), poly lactic glycolic acid (PLGA), poly (c-caprolactone) copolymers, polydioxanone, poly(propylene fumarate) poly(trimethylene carbonate) copolymers, polyhydroxy alkanoates, polyphosphazenes, polyanhydrides, poly(ortho esters), poly(amino acids), or “pseudo”-poly(amino acids).


In some aspects, the expanding member 120 may be configured to allow perfusion of tissues downstream of the expanding member during expansion or inflation of the expanding member 120. Allowing perfusion of tissues downstream also aids in dissolution of the adhesive 117.


Referring to FIG. 4A, in one example, the adhesive 117 may be disposed between the expanding member 120 and a region 115A. The adhesive 117 adheres a portion of the region 115A to the outer surface of the expanding member 120. The adhesive 117 may be applied on the expanding member 120 and/or the vascular device 110, such that it only adheres a proximal and/or distal portion of the region 115A. Referring to FIG. 4C, alternatively, the adhesive 117 may be applied either throughout or at a particular portion of the region 115A. Referring to FIG. 4B, the adhesive 117 may be applied continuously or intermittently on the outer surface of the expanding member 120 or the vascular device 110, depending on the dissolvability and/or fracturability of the adhesive 117. The adhesive 117 may be applied by spray, dip, or other processes.


Referring to FIG. 4D, in one aspect, the adhesive 117 may be applied on the outer surface of the expanding member 120 while the expanding member 120 is uniformly stretched, inflated, partially expanded, and/or in the expanded configuration. For example, the adhesive 117 may be applied on the outer surface of the expanding member 120 when the expanding member 120 is in the expanded configuration and uniformly stretched along its length. In this example, the adhesive 117 may be applied intermittently within the region 115A, such that unadhered areas are formed, as shown in FIG. 4C. The unadhered areas facilitate folding or collapsing of the expanding member 120 and vascular device 110 as the expanding member 120 and vascular device are prepared for deployment within the vasculature and moved to the collapsed configuration.


Alternatively, the adhesive 117 may be applied on the outer surface of the expanding member 120 while the expanding member 120 is deflated, partially collapsed, and/or in the collapsed configuration. In this example, the adhesive 117 may be applied continuously within the region 115A, as shown in FIG. 4B.


In another example, the adhesive 117 may be applied on the outer surface of the expanding member 120 while the expanding member 120 has a portion that is stretched along its length. The stretched portion may correspond to the region 115A of the vascular device 110.


In some aspects, the expanding member 120 and the vascular device 110 are positively engaged, coupled, attached, or adhered such that there is no shear strain in the adhesive 117 when the expanding member 120 and the vascular device 110 are in the expanded configuration. In other aspects, the expanding member 120 and the vascular device 110 are positively engaged, coupled, attached, or adhered such that there is enough shear strain in the adhesive 117, when the expanding member 120 and the vascular device 110 are fully expanded or in the expanded configuration, to fracture or sever the adhesive 117 and thereby release the vascular device 110 from the expanding member 120. In other aspects, the expanding member 120 and the vascular device 110 are positively engaged, coupled, attached, or adhered such that there is enough shear strain in the adhesive 117 when the expanding member 120 and the vascular device 110 are partially expanded to fracture or sever the adhesive 117 and thereby release the vascular device 110 from the expanding member 120 prior to full expansion of the expanding member 120. The shear strain of interest could be axial strain, hoop strain, or a combination of both.


Prior to deployment, the expanding member 120 may be moved to the collapsed configuration, with the vascular device 110 disposed thereon. When in the collapsed configuration, the region 115A of the body 111 will have a higher braid density and lower porosity than other portions of the body 111 due to the adhesive 117 bonding the region 115A to the expanding member 120. During subsequent expansion of the expanding member 120 and the vascular device 110, the overall porosity of the body 111 will decrease as the diameter of the vascular device 110 increases and the axial length of the vascular device 110 shortens. The porosity of the region 115A, however, also decreases and remains less porous than other portions of the body 111 during and after expansion.


Referring to FIGS. 5A-5B, the expanding member 120 may controllably expand the vascular device 110 and attain the predetermined porosity for the region 115B by increasing a diameter of the region 115B of the vascular device 110 to a diameter that is larger than other portions of the vascular device 110. The expanding member 120 may comprise, when expanded, an enlarged region 123A having an enlarged diameter relative to other regions of the expanding member 120. The enlarged region 123A is substantially axially aligned with the region 115B.


The enlarged region 123A of the expanding member 120 increases the diameter of the region 115B to a diameter that is larger than the diameter in other portions of the body 111. Enlarging the diameter of the region 115B causes the members 112 disposed on the other portions of the body 111 to be pulled toward the region 115B, thereby decreasing the porosity within the region 115B. Accordingly, the expanding member 120 causes a reduction in the porosity of the body 111 within the region 115B that is more than the reduction of the porosity of the body 111 outside the region 115B, to thereby attain the predetermined porosity for the region 115B.


In one aspect, the adhesive 117 may be used to positively engage, couple, attach, or adhere the region 115B of the vascular device 110 to the enlarged region 123A of the expanding member 120. The adhesive 117 assists in utilizing the axial shrinkage and radial expansion characteristics of the expanding member 120 to control the porosity of the vascular device 110 by positively engaging, coupling, attaching, or adhering the expanding member 120 to the vascular device 110. The adhesion between the region 115B of the vascular device 110 and the expanding member 120 ensures that upon deployment, the region 115B attains the predetermined porosity.


Once near the treatment site, the adhesive 117 would begin to dissolve. As the expanding member 120 is expanded, the remaining adhesive 117 will be fractured, thereby further facilitating dissolution of the adhesive 117. The expanding member 120 and the vascular device 110 would expand in the same manner, shortening in axial length while increasing in diameter. The enlarged region 123A of the expanding member 120 would expand to a diameter greater than other portions of the expanding member 120, thereby causing the density within the region 115B to increase and the porosity within the region 115B to decrease, more than the other portions of the body 111.


Referring to FIGS. 6A-6B, the expanding member 120 may controllably expand the vascular device 110 and attain the predetermined porosity for the region 115C by storing excess material of the region 115C of the vascular device 110 within a reduced region 123B of the expanding member 120. For example, the expanding member 120 may comprise, when expanded, the reduced region 123B having a reduced diameter relative to other regions of the expanding member 120. The reduced region 123B is substantially axially aligned with the region 115C and provides an area to store the excess material of the region 115C. In other words, the vascular device 110 may be arranged over the expanding member 120 so that the material of the region 115C may be bunched up and collected, in a highly dense arrangement, within the reduced region 123B of the expanding member 120.


In one aspect, the adhesive 117 may be used to adhere the proximal and/or distal portions of the body 111, with the region 115C unadhered, to the expanding member 120. In another example, the adhesive 117 may be disposed intermittently along the reduced region 123B, as shown in FIG. 6A. The adhesive 117 assists in maintaining the excess material of the region 115C within the reduced region 123B of the expanding member 120 so that upon deployment, the region 115C attains the predetermined porosity. Thus, upon expansion of the expanding member 120, the excess material of the region 115C stored at the reduced region 123B of the expanding member 120 will be deployed with comparatively reduced porosity.


Once near the treatment site, the adhesive 117 would begin to dissolve. As the expanding member 120 is expanded, the remaining adhesive 117 will be fractured, thereby further facilitating dissolution of the adhesive 117. The expanding member 120 and the vascular device 110 would expand in the same manner, shortening in axial length while increasing in diameter. The reduced region 123B of the expanding member 120, which houses the excess material of the region 115C, will begin to enlarge and deploy the excess material contained therein.


Referring to FIGS. 7A-7B, the expanding member 120 may controllably expand the vascular device 110 and attain the predetermined porosity for the region 115D by storing excess material of the region 115D of the vascular device 110 within a region 123C disposed between two enlarged regions 124 of the expanding member 120. For example, the expanding member 120 may comprise, when expanded, two enlarged regions 124 having an enlarged diameter relative to a reduced region 123C therebetween. The reduced region 123C has a reduced diameter, is substantially axially aligned with the region 115D, and provides an area to store the excess material of the region 115D. In other words, the vascular device 110 may be arranged over the expanding member 120 so that the material of the region 115D may be bunched up and collected, in a highly dense arrangement, within the reduced region 123C of the expanding member 120.


In one aspect, the adhesive 117 may be used to adhere the proximal and/or distal portions of the body 111, with the region 115D unadhered, to the enlarged regions 124 of the expanding member 120. The adhesive 117 assists in maintaining the excess material of the region 115D within the reduced region 123C of the expanding member 120 so that upon deployment, the region 115D attains the predetermined porosity. Thus, upon expansion of the expanding member 120, the excess material of the region 115D stored at the reduced region 123C of the expanding member 120 will be deployed with comparatively reduced porosity.


Once near the treatment site, the adhesive 117 would begin to dissolve. As the expanding member 120 is expanded, the remaining adhesive 117 will be fractured, thereby further facilitating dissolution of the adhesive 117. The expanding member 120 and the vascular device 110 would expand in the same manner, shortening in axial length while increasing in diameter. The reduced region 123C of the expanding member 120, which houses the excess material of the region 115D, will begin to enlarge and deploy the excess material contained therein.


Radiopaque markers may be located adjacent the proximal or distal portions of the vascular device 110, and may be located at any position along the length of the vascular device 110 between a proximal and distal end of the vascular device 110, including the region 115A-D. The markers may be attached to the vascular device 110 by techniques such as adhesives, heat fusion, interference fit, fasteners, intermediate members, coatings, or by other techniques.


In some embodiments, the markers are comprised of ultrasonic markers, MRI-safe markers, or other markers. In some embodiments ultrasonic markers permit a physician to accurately determine the position of the vascular device 110 within a patient under ultrasonic visualization. Materials for an ultrasonic marker have an acoustical density sufficiently different from the vascular device 110 to provide suitable visualization via ultrasonic techniques. Exemplary materials comprise polymers, metals such as tantalum, platinum, gold, tungsten and alloys of such metals, hollow glass spheres or microspheres, and other materials.


In some embodiments, MRI-safe markers permit a physician to accurately determine the position of the vascular device 110 within a patient under magnetic resonance imaging. Exemplary materials for making MRI-safe marker have a magnetic signature sufficiently different from the vascular device 110 to provide suitable visualization via MRI techniques. Exemplary materials comprise polymers, metals such as tantalum, platinum, gold, tungsten and alloys of such metals, non-ferrous materials, and other materials.


A technique for treating an aneurysm will now be discussed with reference to FIGS. 8A-14. The vascular device 110 may be delivered into a treatment site using the system 100. The system 100 includes the catheter 130, which may for example, be an over the wire (OTW) catheter, a rapid exchange (multiple lumen) catheter, or a fixed wire catheter.


Referring to FIG. 8A, the OTW catheter includes a shaft 131. A proximal portion of the shaft 131 has a manifold 132 affixed thereto. A distal portion of the shaft 131 has the expanding member 120 affixed thereto. The shaft 131 also includes two lumens, a guide wire lumen 133 and an inflation lumen 134 for expanding or inflating the expanding member 120. A proximal end of each lumen 133, 134 is configured to interface with the manifold 132.


Referring to FIG. 8B, the rapid exchange catheter includes a shaft 131 having an inflation lumen 134 extending therethrough. A proximal portion of the shaft 131 has a hub 135 affixed thereto. A distal portion of the shaft 131 has the expanding member 120 affixed thereto. The shaft 131 has two lumens over a distal portion only. The inflation lumen 134 and a guide wire lumen 133 which extends from a distal end of the shaft 131, to a skive 136. At the skive 136, the guide wire lumen 133 terminates and a guide wire communicates with an outer surface of the shaft 131. The inflation lumen 134 is configured to expand or inflate the expanding member 120.


The fixed wire catheter includes a shaft having an inflation lumen only, to which is affixed a hub and the expanding member 120.


Referring to FIG. 9, prior to delivery, the vascular device 110 is mounted to the expanding member 120 either with or without adhesive 117. An outer sheath 140 is disposed over the vascular device 110 and the expanding member 120 to confine, within an annular space between the outer sheath 140 and the expanding member 120, the vascular device 110 in the first, collapsed configuration. The outer sheath 140 also retains the vascular device 110 and the expanding member 120 in an axial elongated and diametrically reduced configuration.


The vascular device 110 and the expanding member 120 may be cooperatively movable within the outer sheath 140 in order to deliver the vascular device 110 to a treatment site, such as an aneurysm, within the vasculature of a patient.


The outer sheath 140 may be configured to be introduced and advanced through the vasculature of the patient. The outer sheath 140 may be made from various thermoplastics, e.g., PTFE, FEP, HDPE, PEEK, etc., which may optionally be lined on the inner surface of the outer sheath 140 or an adjacent surface with a hydrophilic material such as PVP or some other plastic coating. Additionally, either surface may be coated with various combinations of different materials, depending upon the desired results.


The shaft 131 includes the guide wire lumen 133 for allowing a guide wire 150 to extend therethrough. The shaft 131 may also include a reduced diameter at a distal region 137 to provide sufficient annular space in which the vascular device 110 is stowed. In this example, the expanding member 120 would be disposed on the reduced diameter region 137 of the shaft 131.


Radiopaque markers may be provided at various locations along the length of the system 100. For example, an enlarged distal tip 138 of the shaft 131 may be radiopaque. In another example, radiopaque markers may be provided on the reduced diameter distal region 137 of the shaft, beneath the distal and proximal end of the vascular device 110. In yet another example, a radiopaque marker 160 may be disposed on the shaft 131 adjacent to a longitudinal center of the vascular device 110 and/or the expanding member 120.


In one aspect, the vascular devices 110 may be configured with regions 115A-D having different axial lengths. A physician may select the appropriate vascular device 110 based on a size of the neck of the aneurysm and the axial length of the region 115A-D. For example, based on the axial length of the region 115A-D and a length of a neck of the aneurysm “Ln,” the vascular device 110 may be selected such that the axial length of the region 115A-D, when the vascular device 110 is in the second, expanded configuration, is longer than the length of the neck of the aneurysm.


In another aspect, the system 100 may be manufactured to ship with the expanding member 120 and the vascular device 110 in the expanded configuration. In this example, after the system 100 is selected such that the as-delivered axial length of the region 115A-D is longer than the length of the aneurysm, the physician may draw the vascular device 110 and the expanding member 120 assembly proximally into the outer sheath 140 to compress the vascular device and the expanding member 120 assembly. In an alternative embodiment, the system 100 may be manufactured to ship with the expanding member 120 and the vascular device 110 in the collapsed configuration, preloaded in the outer sheath 140.


Referring to FIG. 9, the system 100 is advanced percutaneously over the guide wire 150 to the treatment site, in this example to the site of an aneurysm 210. Specifically, the vascular device 110 may be positioned in a vessel 200 at an ostium or the neck of the aneurysm 210. In one aspect, the radiopaque marker 160 may be positioned distal to a distal lateral wall of the aneurysm 210, thereby offsetting the region 115A-D from the ostium of the aneurysm 210 prior to expanding the vascular device 110. During delivery, any dissolvable adhesive 117 disposed between the vascular device 110 and the expanding member 120 is protected from dissolving by the outer sheath 140. Specifically, the outer sheath 140 covers the vascular device 110 and the expanding member 120 assembly and thereby prevents any fluids, such as blood, from coming into contact with the adhesive 117.


Referring to FIG. 10, after navigating the system 100 to the treatment site within the patient, the outer sheath 140 is withdrawn proximally while maintaining the position of the shaft 131 to thereby expose a distal portion of the shaft 131, the expanding member 120, and the vascular device 110. The outer sheath 140 is withdrawn until a distal end of the outer sheath 140 is proximal of the vascular device 110 and the expanding member 120 assembly.


If the vascular device 110 comprises a self-expanding stent, then portions of the vascular device that may be unadhered to the expanding member 120 may partially diametrically expand and partially axially shorten. In this example the region 115A-D will maintain a higher density and lower porosity than other portions of the body 111, during and after deployment, because of the adhesive 117 disposed between the region 115A-D and the expanding member 120. The adhesive 117 thereby allows the expandable member 120 to controllably expand the vascular device 110 and attain the predetermined porosity for the region 115A-D by positively engaging the vascular device 110. Alternatively, if the vascular device 110 does not comprise a self-expanding stent, then the vascular device 110 remains on the expanding member 120. As the outer sheath 140 is withdrawn, thereby exposing the vascular device 110 and the expanding member 120 assembly, the adhesive 117 begins to make contact with fluids, such as blood. The adhesive 117 begins to dissolve due to the contact with the fluid.


Referring to FIG. 11, as the expanding member 120 is partially expanded or inflated using the inflation lumen 134, the expanding member 120 and hence, the vascular device 110, partially diametrically expand and partially axially shorten. During expansion of the expanding member 120, the inner member 125 also axially shortens by the same amount as the expanding member 120 and/or the vascular device 110.


Referring to FIG. 12, the system 100 is then withdrawn proximally, until the radiopaque marker 160 is centered along the length of the ostium or neck of the aneurysm 210. In other words, after the vascular device 110 has been repositioned such that the region 115A-D is centered along the length of the ostium, the region 115A-D will cover the ostium or neck of the aneurysm 210 when the vascular device 110 is in the second, expanded configuration.


The expanding member 120 is then expanded to the fully expanded configuration, thereby fully deploying the vascular device 110. The expanding member 120 will diametrically expand and axially shrink, while maintaining the vascular device 110 to its outer surface due to the remaining adhesive 117 disposed between the vascular device 110 and the expanding member. The expanding member 120 controllably expands the vascular device 110 such that the vascular device 110 attains the predetermined porosity at the region 115A-D. During deployment, the expanding member 120 causes a reduction in the porosity of the body 111 within the region 115A-D that is more than the reduction of the porosity of the body 111 outside the region 115A-D, thereby attaining the predetermined porosity for the region 115A-D.


The adhesive 117 disposed between the expanding member 120 and the vascular device 110 may dissolve and/or fracture during or after expansion of the expanding member 120, thereby releasing the vascular device 110 from the expanding member 120.


The expanding member 120 thereby causes the region 115A-D to attain the pre-programmed porosity regardless of the endless variety of physician induced movements that can occur during the deployment of the vascular device 110. Stated another way, the porosity of the region 115A-D is relatively insensitive to physician applied motions during deployment of the vascular device 110.


Referring to FIG. 13, once the entire vascular device 110 is fully expanded, the expanding member 120 is collapsed or deflated. Referring to FIG. 14, thereafter, the catheter 130, along with the outer sheath 140, shaft 131, expanding member 120, and guide wire 150 may be withdrawn from the body.


The region 115A-D of the vascular device 100 has a significantly lower porosity compared to other portions of the body 111. Due to the lower porosity of the region 115A-D, less blood flows into the aneurysm 210 such that substantial thrombosis may occur within the aneurysm 210.


In one arrangement, the vascular device 110 may be comprised of metal, polymer, ceramic, permanent enduring materials, and may comprise either of or both of non-bioabsorbable and bioabsorbable materials. Exemplary materials include, but are not limited to, NITINOL®, stainless steel, cobalt chromium alloys, Elgiloy, magnesium alloys, polylactic acid, poly glycolic acid, poly ester amide (PEA), poly ester urethane (PEU), amino acid based bioanalogous polymers, tungsten, tantalum, platinum, polymers, bio-polymers, ceramics, bio-ceramics, or metallic glasses. Part or all of the medical device may elute over time substances such as drugs, biologics, gene therapies, antithrombotics, coagulants, anti-inflammatory drugs, immunomodulator drugs, anti-proliferatives, migration inhibitors, extracellular matrix modulators, healing promoters, re-endothelialization promoters, or other materials. In some embodiments, the vascular device 110 may be formed from materials having shape memory properties. In some embodiments, the vascular device 110 may be finished by processes to remove slag. In some embodiments, the vascular device 110 may be subjected to a tempering treatment at temperatures customarily applied to the material so that the impressed structure is permanently established.


The vascular device 110 may have various lengths and diameters. For example, the vascular device 110 may have specific cross-sectional diameters, the diameters being measured when the vascular device 110 is fully free to expand, ranging from about 2 mm to about 6 mm. If the vascular device 110 has a diameter between 3 mm and 4 mm, it may be used in a size 18 microcatheters (i.e., microcatheters with an inner diameter of approximately 0.21 inch). If the vascular device 110 has a diameter between 5 mm and 6 mm, it may be used in a size 27 microcatheters (i.e., microcatheters with an inner diameter of approximately 0.027 inch). However, other suitable cross-sectional diameters may be used without deviating from the scope of the subject technology. In some embodiments, the vascular device 110 may have lengths, measured proximally to distally along the longitudinal axis of the vascular device 110, ranging from 15 mm to 40 mm, though other ranges and sizes are also possible.


Skilled artisans may implement the described functionality in varying ways for each particular application. Various components and blocks may be arranged differently (for example, arranged in a different order, or partitioned in a different way) all without departing from the scope of the subject technology. It is understood that the specific order or hierarchy of steps in the processes disclosed is an illustration of exemplary approaches. Based upon design preferences, it is understood that the specific order or hierarchy of steps in the processes may be rearranged. Some of the steps may be performed simultaneously. The accompanying method claims present elements of the various steps in a sample order, and are not meant to be limited to the specific order or hierarchy presented.


The previous description is provided to enable any person skilled in the art to practice the various aspects described herein. The previous description provides various examples of the subject technology, and the subject technology is not limited to these examples. Various modifications to these aspects will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other aspects. Thus, the claims are not intended to be limited to the aspects shown herein, but is to be accorded the full scope consistent with the language claims, wherein reference to an element in the singular is not intended to mean “one and only one” unless specifically so stated, but rather “one or more.” Unless specifically stated otherwise, the term “some” refers to one or more. Pronouns in the masculine (for example, his) include the feminine and neuter gender (for example, her and its) and vice versa. Headings and subheadings, if any, are used for convenience only and do not limit the invention.


A phrase such as an “aspect” does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology. A disclosure relating to an aspect may apply to all configurations, or one or more configurations. An aspect may provide one or more examples. A phrase such as an aspect may refer to one or more aspects and vice versa. A phrase such as an “aspect” does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology. A disclosure relating to an aspect may apply to all aspects, or one or more aspects. An aspect may provide one or more examples. A phrase such as an “aspect” may refer to one or more aspects and vice versa. A phrase such as a “configuration” does not imply that such configuration is essential to the subject technology or that such configuration applies to all configurations of the subject technology. A disclosure relating to a configuration may apply to all configurations, or one or more configurations. A configuration may provide one or more examples. A phrase such as a “configuration” may refer to one or more configurations and vice versa.


The word “exemplary” is used herein to mean “serving as an example or illustration.” Any aspect or design described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other aspects or designs.


All structural and functional equivalents to the elements of the various aspects described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and are intended to be encompassed by the claims. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the claims. No claim element is to be construed under the provisions of 35 U.S.C. §112, sixth paragraph, unless the element is expressly recited using the phrase “means for” or, in the case of a method claim, the element is recited using the phrase “step for.” Furthermore, to the extent that the term “include,” “have,” or the like is used in the description or the claims, such term is intended to be inclusive in a manner similar to the term “comprise” as “comprise” is interpreted when employed as a transitional word in a claim.

Claims
  • 1. A system for treating a patient, the system comprising: an expandable vascular device comprising a body having a porosity affectable by adjusting an axial length of the body, andan expanding member positioned within a central lumen of the device, the expanding member being engageable with the body such that, as the body is radially expanded from a collapsed configuration and while engaged by the expanding member, a porosity within a region of the body is changed more than a porosity outside the region of the body is changed.
  • 2. The system of claim 1, wherein the body comprises a braided structure.
  • 3. The system of claim 1, wherein the body comprises a self-expanding structure.
  • 4. The system of claim 1, wherein an axial length of the expanding member in the collapsed configuration is about 200-500% longer than the axial length of the expanding member in an expanded configuration.
  • 5. The system of claim 4, wherein a change in the axial length of the expanding member from the collapsed configuration to the expanded configuration is the same as a change in the axial length of the body from a body collapsed configuration to a body expanded configuration.
  • 6. The system of claim 1, further comprising an adhesive disposed between the expanding member and the region for adhering a portion of the region to the expanding member.
  • 7. The system of claim 1, further comprising a corrugated tube disposed within the expanding member, the corrugated tube configured to axially shorten as the expanding member is inflated.
  • 8. The system of claim 1, wherein the expanding member comprises, when expanded, an enlarged region having an enlarged diameter relative to other regions of the expanding member, the enlarged region being substantially axially aligned with the body region.
  • 9. The system of claim 8, further comprising an adhesive disposed between the enlarged region of the expanding member and the body region.
  • 10. The system of claim 1, wherein the expanding member comprises, when expanded, a reduced region having a reduced diameter relative to other regions of the expanding member, the reduced region being substantially axially aligned with the body region.
  • 11. The system of claim 10, further comprising an adhesive disposed proximally or distally of the reduced region of the expanding member.
  • 12. The system of claim 1, wherein the expanding member comprises, when expanded, two enlarged regions having an enlarged diameter relative to a reduced region therebetween, having a reduced diameter, the reduced region being substantially axially aligned with the body region.
  • 13. The system of claim 12, further comprising an adhesive disposed between the enlarged regions and the body.
  • 14. A delivery system for a vascular device, the delivery system comprising: a catheter having a lumen;a guide wire extending through the catheter lumen;a vascular device having a porosity affectable by adjustment of an axial length of the device; andan expanding member disposed within a distal portion of the catheter, the expanding member having an axial length that is adjustable as the expanding member is radially expanded;wherein the expanding member is engageable with a region of the device such that, during adjustment of the axial length of the expanding member and while the expanding member engages the region, a porosity within the region of the device is changed more than a porosity outside the region of the device is changed.
  • 15. The system of claim 14, wherein the axial length of the expanding member in a collapsed configuration is about 200-500% longer than the axial length of the expanding member in a radially expanded configuration.
  • 16. The system of claim 15, wherein a change in the axial length of the expanding member from the collapsed configuration to the radially expanded configuration is the same as a change in the axial length of the device from a device collapsed configuration to a device expanded configuration.
  • 17. The system of claim 14, further comprising an adhesive disposed between the expanding member and the region for adhering a portion of the region to the expanding member.
  • 18. The system of claim 14, wherein the expanding member comprises, when radially expanded, an enlarged region having an enlarged diameter relative to other regions of the expanding member, the enlarged region being substantially axially aligned with the body region.
  • 19. The system of claim 14, wherein the expanding member comprises, when radially expanded, a reduced region having a reduced diameter relative to other regions of the expanding member, the reduced region being substantially axially aligned with the body region.
  • 20. The system of claim 14, wherein the expanding member comprises, when radially expanded, two enlarged regions having an enlarged diameter relative to a reduced region therebetween, having a reduced diameter, the reduced region being substantially axially aligned with the body region.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/826,971, filed Mar. 14, 2013, which claims priority benefit of U.S. Provisional Application Ser. No. 61/720,154, filed Oct. 30, 2012, each of which is hereby incorporated herein by reference in its entirety.

US Referenced Citations (648)
Number Name Date Kind
2919467 Mercer Jan 1960 A
4321711 Mano Mar 1982 A
4503569 Dotter Mar 1985 A
4512338 Balko et al. Apr 1985 A
4538622 Samson et al. Sep 1985 A
4572186 Gould et al. Feb 1986 A
4580568 Gianturco Apr 1986 A
4655771 Wallsten Apr 1987 A
4681110 Wiktor Jul 1987 A
4733665 Palmaz Mar 1988 A
4743251 Barra May 1988 A
4768507 Fischell et al. Sep 1988 A
4776337 Palmaz Oct 1988 A
4856516 Hillstead Aug 1989 A
4954126 Wallsten Sep 1990 A
5011488 Ginsburg Apr 1991 A
5035706 Giantureo et al. Jul 1991 A
5041126 Gianturco Aug 1991 A
5061275 Wallsten et al. Oct 1991 A
5108416 Ryan et al. Apr 1992 A
5160341 Brenneman et al. Nov 1992 A
5180368 Garrison Jan 1993 A
5192297 Hull Mar 1993 A
5197978 Hess Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5209731 Sterman et al. May 1993 A
5242399 Lau et al. Sep 1993 A
5246420 Kraus et al. Sep 1993 A
5246445 Yachia et al. Sep 1993 A
5330500 Song Jul 1994 A
5344426 Lau et al. Sep 1994 A
5360443 Barone et al. Nov 1994 A
5382259 Phelps et al. Jan 1995 A
5401257 Chevalier, Jr. et al. Mar 1995 A
5405377 Cragg Apr 1995 A
5405380 Gianotti et al. Apr 1995 A
5415637 Khosravi May 1995 A
5421826 Crocker et al. Jun 1995 A
5423849 Engelson et al. Jun 1995 A
5449372 Schmaltz et al. Sep 1995 A
5458615 Klemm et al. Oct 1995 A
5476505 Limon Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5484444 Braunschweiler Jan 1996 A
5489295 Piplani et al. Feb 1996 A
5507767 Maeda et al. Apr 1996 A
5507768 Lau et al. Apr 1996 A
5522822 Phelps et al. Jun 1996 A
5534007 St. Germain et al. Jul 1996 A
5545208 Wolff et al. Aug 1996 A
5546880 Ronyak et al. Aug 1996 A
5549662 Fordenbacher Aug 1996 A
5562641 Flomenblit et al. Oct 1996 A
5562728 Lazarus et al. Oct 1996 A
5591225 Okuda Jan 1997 A
5599291 Balbierz et al. Feb 1997 A
5601593 Freitag Feb 1997 A
5607466 Imbert et al. Mar 1997 A
5609625 Piplani et al. Mar 1997 A
5626602 Gianotti et al. May 1997 A
5628783 Quiachon et al. May 1997 A
5628788 Pinchuk May 1997 A
5632771 Boatman et al. May 1997 A
5632772 Alcime et al. May 1997 A
5636641 Fariabi Jun 1997 A
5637113 Tartaglia et al. Jun 1997 A
5639278 Dereume et al. Jun 1997 A
5645559 Hachtman et al. Jul 1997 A
D381932 Walshe et al. Aug 1997 S
5667522 Flomenblit et al. Sep 1997 A
5674276 Andersen et al. Oct 1997 A
5683451 Lenker et al. Nov 1997 A
5690120 Jacobsen Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5695499 Helgerson et al. Dec 1997 A
5700269 Pinchuk et al. Dec 1997 A
5702418 Ravenscroft Dec 1997 A
5709702 Cogita Jan 1998 A
5709703 Lukic et al. Jan 1998 A
5718159 Thompson Feb 1998 A
5725570 Heath Mar 1998 A
5733327 Igaki et al. Mar 1998 A
5735859 Fischell et al. Apr 1998 A
5741325 Chaikof et al. Apr 1998 A
5741333 Frid Apr 1998 A
5746765 Kleshinski et al. May 1998 A
5749883 Halpern May 1998 A
5749920 Quiachon et al. May 1998 A
5769884 Solovay Jun 1998 A
5769885 Quiachon et al. Jun 1998 A
5776099 Tremulis Jul 1998 A
5776142 Gunderson Jul 1998 A
5782909 Quiachon et al. Jul 1998 A
5797952 Klein Aug 1998 A
5800518 Piplani et al. Sep 1998 A
5810837 Hofmann et al. Sep 1998 A
5817102 Johnson et al. Oct 1998 A
5817105 Van Der Brug Oct 1998 A
5824039 Piplani et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824042 Lombardi et al. Oct 1998 A
5824044 Quiachon et al. Oct 1998 A
5824058 Ravenscroft et al. Oct 1998 A
5830229 Konya et al. Nov 1998 A
5833632 Jacobsen et al. Nov 1998 A
5836868 Ressemann et al. Nov 1998 A
5843168 Dang Dec 1998 A
5868754 Levine et al. Feb 1999 A
5876419 Carpenter et al. Mar 1999 A
5876445 Andersen Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5902266 Leone et al. May 1999 A
5902317 Kleshinski et al. May 1999 A
5906640 Penn et al. May 1999 A
5911717 Jacobsen et al. Jun 1999 A
5916194 Jacobsen et al. Jun 1999 A
5919204 Lukic et al. Jul 1999 A
5928260 Chin et al. Jul 1999 A
5944728 Bates Aug 1999 A
5951599 McCrory Sep 1999 A
5957973 Quiachon et al. Sep 1999 A
5957974 Thompson et al. Sep 1999 A
5964797 Ho Oct 1999 A
5980530 Willard Nov 1999 A
5980533 Holman Nov 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
6012277 Prins et al. Jan 2000 A
6014919 Jacobsen et al. Jan 2000 A
6015432 Rakos et al. Jan 2000 A
6017319 Jacobsen et al. Jan 2000 A
6019778 Wilson et al. Feb 2000 A
6019786 Thompson Feb 2000 A
6022369 Jacobsen et al. Feb 2000 A
6024754 Engelson Feb 2000 A
6024763 Lenker et al. Feb 2000 A
6027516 Kolobow et al. Feb 2000 A
6033436 Steinke et al. Mar 2000 A
6039721 Johnson Mar 2000 A
6039758 Quiachon et al. Mar 2000 A
6042589 Marianne Mar 2000 A
6051021 Frid Apr 2000 A
6056993 Leidner et al. May 2000 A
6063111 Hieshima et al. May 2000 A
6074407 Levine et al. Jun 2000 A
6077295 Limon et al. Jun 2000 A
6080191 Summers Jun 2000 A
6083257 Taylor et al. Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096052 Callister et al. Aug 2000 A
6102942 Ahari Aug 2000 A
6123712 Di Caprio et al. Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6132459 Piplani et al. Oct 2000 A
6139543 Esch et al. Oct 2000 A
6146415 Fitz Nov 2000 A
6149680 Shelso et al. Nov 2000 A
6159228 Frid et al. Dec 2000 A
6161399 Jayaraman Dec 2000 A
6165194 Denardo Dec 2000 A
6165210 Lau et al. Dec 2000 A
6165213 Goicoechea et al. Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6174330 Stinson Jan 2001 B1
6183410 Jacobsen et al. Feb 2001 B1
6183508 Stinson et al. Feb 2001 B1
6187013 Stoltze et al. Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
6197046 Piplani et al. Mar 2001 B1
6203569 Wijay Mar 2001 B1
6206868 Parodi Mar 2001 B1
6210400 Hebert et al. Apr 2001 B1
6210434 Quiachon et al. Apr 2001 B1
6210435 Piplani et al. Apr 2001 B1
6214038 Piplani et al. Apr 2001 B1
6214042 Jacobsen et al. Apr 2001 B1
6221102 Baker et al. Apr 2001 B1
6224609 Ressemann et al. May 2001 B1
6224829 Piplani et al. May 2001 B1
6231598 Berry et al. May 2001 B1
6235050 Quiachon et al. May 2001 B1
6241759 Piplani et al. Jun 2001 B1
6245087 Addis Jun 2001 B1
6245103 Stinson Jun 2001 B1
6251132 Ravenscroft et al. Jun 2001 B1
6258115 Dubrul Jul 2001 B1
6260458 Jacobsen et al. Jul 2001 B1
6261305 Marotta et al. Jul 2001 B1
6261316 Shaolian et al. Jul 2001 B1
6264671 Stack Jul 2001 B1
6264689 Colgan et al. Jul 2001 B1
6270523 Herweck et al. Aug 2001 B1
6280465 Cryer Aug 2001 B1
6283991 Cox et al. Sep 2001 B1
6287331 Heath Sep 2001 B1
6287333 Appling et al. Sep 2001 B1
6290721 Heath Sep 2001 B1
6299636 Schmitt et al. Oct 2001 B1
6302810 Yokota Oct 2001 B2
6302893 Limon et al. Oct 2001 B1
6309353 Cheng et al. Oct 2001 B1
6322576 Wallace et al. Nov 2001 B1
6322586 Monroe et al. Nov 2001 B1
6322587 Quiachon et al. Nov 2001 B1
6325826 Vardi et al. Dec 2001 B1
6334871 Dor et al. Jan 2002 B1
6336938 Kavteladze et al. Jan 2002 B1
6340367 Stinson et al. Jan 2002 B1
6340368 Verbeck Jan 2002 B1
6342068 Thompson Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6348063 Yassour et al. Feb 2002 B1
6350199 Williams et al. Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6355051 Sisskind et al. Mar 2002 B1
6355061 Quaichon Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6368339 Amplatz Apr 2002 B1
6368344 Fitz Apr 2002 B1
6368557 Piplani et al. Apr 2002 B1
6375670 Greenhalgh Apr 2002 B1
6375676 Cox Apr 2002 B1
6379618 Piplani et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6389946 Frid May 2002 B1
6395017 Dwyer et al. May 2002 B1
6395021 Hart et al. May 2002 B1
6395022 Piplani et al. May 2002 B1
6398802 Yee Jun 2002 B1
6409683 Fonseca et al. Jun 2002 B1
6413235 Parodi Jul 2002 B1
6416519 VanDusseldorp Jul 2002 B1
6416536 Yee Jul 2002 B1
6419693 Fariabi Jul 2002 B1
6428489 Jacobsen et al. Aug 2002 B1
6440088 Jacobsen et al. Aug 2002 B1
6443971 Boylan et al. Sep 2002 B1
6443979 Stalker Sep 2002 B1
6454999 Farhangnia et al. Sep 2002 B1
6468301 Amplatz et al. Oct 2002 B1
6477768 Wildner Nov 2002 B1
6478778 Jacobsen et al. Nov 2002 B1
6482221 Hebert et al. Nov 2002 B1
6488705 Schmitt et al. Dec 2002 B2
6491648 Cornish et al. Dec 2002 B1
6494895 Addis Dec 2002 B2
6497711 Plaia et al. Dec 2002 B1
6503450 Afzal Jan 2003 B1
6514261 Randall et al. Feb 2003 B1
6514285 Pinchasik Feb 2003 B1
6524299 Tran et al. Feb 2003 B1
6527763 Esch et al. Mar 2003 B2
6533811 Ryan et al. Mar 2003 B1
6540778 Quiachon et al. Apr 2003 B1
6547779 Levine Apr 2003 B2
6551352 Clerc et al. Apr 2003 B2
6572646 Boylan et al. Jun 2003 B1
6576006 Limon et al. Jun 2003 B2
6582460 Cryer Jun 2003 B1
6582461 Burmeister et al. Jun 2003 B1
6589273 McDermott Jul 2003 B1
6592616 Stack et al. Jul 2003 B1
6595989 Scheer Jul 2003 B1
6602271 Adams et al. Aug 2003 B2
6602280 Chobotov Aug 2003 B2
6605110 Harrison Aug 2003 B2
6613075 Healy et al. Sep 2003 B1
6613078 Barone Sep 2003 B1
6622604 Chouinard et al. Sep 2003 B1
6623518 Thompson et al. Sep 2003 B2
6635068 Dubrul et al. Oct 2003 B1
6638243 Kupiecki Oct 2003 B2
6645240 Yee Nov 2003 B2
6646218 Campbell et al. Nov 2003 B1
6652508 Griffin Nov 2003 B2
6652574 Jayaraman Nov 2003 B1
6656212 Ravenscroft et al. Dec 2003 B2
6656218 Denardo et al. Dec 2003 B1
6660024 Flaherty Dec 2003 B1
6660032 Klumb et al. Dec 2003 B2
6663666 Quiachon et al. Dec 2003 B1
6666881 Richter et al. Dec 2003 B1
6669719 Wallace Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673100 Diaz et al. Jan 2004 B2
6679893 Tran Jan 2004 B1
6682557 Quiachon et al. Jan 2004 B1
6685735 Ahari Feb 2004 B1
6689120 Gerdts Feb 2004 B1
6689162 Thompson Feb 2004 B1
6699274 Stinson Mar 2004 B2
6702843 Brown et al. Mar 2004 B1
6709454 Cox et al. Mar 2004 B1
6712834 Yassour et al. Mar 2004 B2
6726700 Levine Apr 2004 B1
6733519 Lashinski et al. May 2004 B2
6740105 Yodfat et al. May 2004 B2
6740112 Yodfat et al. May 2004 B2
6743219 Dwyer et al. Jun 2004 B1
6755855 Yurek et al. Jun 2004 B2
6758885 Leffel et al. Jul 2004 B2
6767361 Quiachon et al. Jul 2004 B2
6773446 Dwyer et al. Aug 2004 B1
6793667 Hebert et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6814748 Baker et al. Nov 2004 B1
6818006 Douk et al. Nov 2004 B2
6833003 Jones et al. Dec 2004 B2
6849084 Rabkin et al. Feb 2005 B2
6858034 Hijlkema et al. Feb 2005 B1
6860893 Wallace et al. Mar 2005 B2
6860898 Stack et al. Mar 2005 B2
6860899 Rivelli, Jr. Mar 2005 B1
6860900 Clerc et al. Mar 2005 B2
6860901 Baker et al. Mar 2005 B1
6866677 Douk et al. Mar 2005 B2
6866679 Kusleika Mar 2005 B2
6866680 Yassour et al. Mar 2005 B2
6881221 Golds Apr 2005 B2
6887267 Dworschak et al. May 2005 B2
6890337 Feeser et al. May 2005 B2
6893451 Cano et al. May 2005 B2
6918921 Brady et al. Jul 2005 B2
6932837 Amplatz et al. Aug 2005 B2
6936055 Ken et al. Aug 2005 B1
6955685 Escamilla et al. Oct 2005 B2
6960227 Jones et al. Nov 2005 B2
6964670 Shah et al. Nov 2005 B1
6964672 Brady et al. Nov 2005 B2
6969396 Krolik et al. Nov 2005 B2
6976991 Hebert et al. Dec 2005 B2
6989024 Hebert et al. Jan 2006 B2
6994721 Israel Feb 2006 B2
7001422 Escamilla et al. Feb 2006 B2
7004962 Stinson Feb 2006 B2
7004964 Thompson et al. Feb 2006 B2
7011675 Hemerick et al. Mar 2006 B2
7037330 Rivelli, Jr. et al. May 2006 B1
7041129 Rourke et al. May 2006 B2
7066951 Chobotov Jun 2006 B2
7069835 Nishri et al. Jul 2006 B2
7074236 Rabkin et al. Jul 2006 B2
7093527 Rapaport et al. Aug 2006 B2
7101392 Heath Sep 2006 B2
7107105 Bjorklund et al. Sep 2006 B2
7118539 Vrba et al. Oct 2006 B2
7118594 Quiachon et al. Oct 2006 B2
7122050 Randall et al. Oct 2006 B2
7137990 Hebert et al. Nov 2006 B2
7166125 Baker et al. Jan 2007 B1
7169170 Widenhouse Jan 2007 B2
7169172 Levine et al. Jan 2007 B2
7172617 Colgan et al. Feb 2007 B2
7192434 Anderson et al. Mar 2007 B2
7195639 Quiachon et al. Mar 2007 B2
7195648 Jones et al. Mar 2007 B2
7201768 Diaz et al. Apr 2007 B2
7201769 Jones et al. Apr 2007 B2
7211109 Thompson May 2007 B2
7213495 McCullagh et al. May 2007 B2
7220271 Clubb et al. May 2007 B2
7235096 Van Tassel et al. Jun 2007 B1
7264632 Wright et al. Sep 2007 B2
7275471 Nishri et al. Oct 2007 B2
7279005 Stinson Oct 2007 B2
7279208 Goffena et al. Oct 2007 B1
7294137 Riveili, Jr. et al. Nov 2007 B2
7294146 Chew et al. Nov 2007 B2
7300456 Andreas et al. Nov 2007 B2
7300460 Levine et al. Nov 2007 B2
7306624 Yodfat et al. Dec 2007 B2
7309351 Escamilla et al. Dec 2007 B2
7311031 McCullagh et al. Dec 2007 B2
7320702 Hammersmark et al. Jan 2008 B2
7323001 Clubb et al. Jan 2008 B2
7331973 Gesswein et al. Feb 2008 B2
7331976 McGuckin, Jr. et al. Feb 2008 B2
7331985 Thompson et al. Feb 2008 B2
7338518 Chobotov Mar 2008 B2
7438712 Chouinard Oct 2008 B2
7462192 Norton et al. Dec 2008 B2
7468070 Henry et al. Dec 2008 B2
7470282 Shelso Dec 2008 B2
7473271 Gunderson Jan 2009 B2
7491224 Cox et al. Feb 2009 B2
7520893 Rivelli, Jr. Apr 2009 B2
RE40816 Taylor et al. Jun 2009 E
7572288 Cox Aug 2009 B2
7572290 Yodfat et al. Aug 2009 B2
7588597 Frid Sep 2009 B2
7695507 Rivelli, Jr. et al. Apr 2010 B2
7763011 Ortiz et al. Jul 2010 B2
7771463 Ton et al. Aug 2010 B2
7854760 Molaei et al. Dec 2010 B2
7901447 Molaei et al. Mar 2011 B2
7942925 Yodfat et al. May 2011 B2
8007529 Yan Aug 2011 B2
8092486 Berrada et al. Jan 2012 B2
8092508 Leynov et al. Jan 2012 B2
8192484 Frid Jun 2012 B2
8382825 Garcia et al. Feb 2013 B2
8394119 Zaver et al. Mar 2013 B2
8398701 Berez et al. Mar 2013 B2
8617234 Garcia et al. Dec 2013 B2
8623067 Berez et al. Jan 2014 B2
8628564 Berez et al. Jan 2014 B2
8764817 Sheldon Jul 2014 B2
8801772 Shobayashi et al. Aug 2014 B2
8979918 Murayama Mar 2015 B2
9050205 Berez et al. Jun 2015 B2
9114001 Kusleika et al. Aug 2015 B2
9125659 Berez et al. Sep 2015 B2
9301831 Kusleika Apr 2016 B2
9452070 Kusleika Sep 2016 B2
20010027338 Greenberg Oct 2001 A1
20010044651 Steinke et al. Nov 2001 A1
20010049547 Moore Dec 2001 A1
20010056299 Thompson Dec 2001 A1
20020004667 Adams et al. Jan 2002 A1
20020007194 Plowiecki Jan 2002 A1
20020029061 Amplatz et al. Mar 2002 A1
20020035396 Heath Mar 2002 A1
20020062091 Jacobsen et al. May 2002 A1
20020078808 Jacobsen et al. Jun 2002 A1
20020082558 Samson et al. Jun 2002 A1
20020087119 Parodi Jul 2002 A1
20020111633 Stoltze et al. Aug 2002 A1
20020111648 Kusleika et al. Aug 2002 A1
20020120323 Thompson et al. Aug 2002 A1
20020138133 Lenz et al. Sep 2002 A1
20020143361 Douk et al. Oct 2002 A1
20020143384 Ozasa Oct 2002 A1
20020169473 Sepetka et al. Nov 2002 A1
20020169474 Kusleika et al. Nov 2002 A1
20020173839 Leopold et al. Nov 2002 A1
20020188314 Anderson et al. Dec 2002 A1
20020193864 Khosravi et al. Dec 2002 A1
20030009215 Mayer Jan 2003 A1
20030023299 Amplatz et al. Jan 2003 A1
20030069522 Jacobsen et al. Apr 2003 A1
20030100945 Yodfat et al. May 2003 A1
20030130684 Brady et al. Jul 2003 A1
20030135258 Andreas et al. Jul 2003 A1
20030163155 Haverkost et al. Aug 2003 A1
20030163156 Hebert et al. Aug 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030212429 Keegan Nov 2003 A1
20030212430 Bose et al. Nov 2003 A1
20040024416 Yodfat et al. Feb 2004 A1
20040030265 Murayama et al. Feb 2004 A1
20040044395 Nelson Mar 2004 A1
20040073300 Chouinard et al. Apr 2004 A1
20040088037 Nachreiner et al. May 2004 A1
20040093010 Gesswein et al. May 2004 A1
20040098099 McCullagh et al. May 2004 A1
20040133223 Weber Jul 2004 A1
20040153117 Clubb et al. Aug 2004 A1
20040162606 Thompson Aug 2004 A1
20040172055 Huter et al. Sep 2004 A1
20040186368 Ramzpoor et al. Sep 2004 A1
20040193178 Nikolchev Sep 2004 A1
20040193179 Nikolchev Sep 2004 A1
20040193208 Talpade et al. Sep 2004 A1
20040199243 Yodfat Oct 2004 A1
20040210235 Deshmukh et al. Oct 2004 A1
20040215332 Frid Oct 2004 A1
20040220585 Nikolchev Nov 2004 A1
20040220608 D'Aquanni et al. Nov 2004 A1
20040220663 Rivelli Nov 2004 A1
20040254628 Nazzaro et al. Dec 2004 A1
20040260331 D'Aquanni et al. Dec 2004 A1
20050004595 Boyle et al. Jan 2005 A1
20050021075 Bonnette et al. Jan 2005 A1
20050033407 Weber et al. Feb 2005 A1
20050038447 Huffmaster Feb 2005 A1
20050051243 Forbes Jones et al. Mar 2005 A1
20050055047 Greenhalgh Mar 2005 A1
20050059889 Mayer Mar 2005 A1
20050060017 Fischell et al. Mar 2005 A1
20050090888 Hines et al. Apr 2005 A1
20050101989 Cully et al. May 2005 A1
20050137680 Ortiz et al. Jun 2005 A1
20050149111 Kanazawa et al. Jul 2005 A1
20050165441 McGuckin et al. Jul 2005 A1
20050177186 Cully et al. Aug 2005 A1
20050192620 Cully et al. Sep 2005 A1
20050197689 Molaei Sep 2005 A1
20050209672 George et al. Sep 2005 A1
20050209678 Henkes et al. Sep 2005 A1
20050246010 Alexander et al. Nov 2005 A1
20050267568 Berez et al. Dec 2005 A1
20050283220 Gobran et al. Dec 2005 A1
20050288764 Snow Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060020324 Schmid et al. Jan 2006 A1
20060036309 Hebert et al. Feb 2006 A1
20060089703 Escamilla et al. Apr 2006 A1
20060095213 Escamilla et al. May 2006 A1
20060111771 Ton et al. May 2006 A1
20060116713 Sepetka et al. Jun 2006 A1
20060116750 Hebert et al. Jun 2006 A1
20060184238 Kaufmann et al. Aug 2006 A1
20060195118 Richardson Aug 2006 A1
20060206148 Khairkhahan et al. Sep 2006 A1
20060206200 Garcia et al. Sep 2006 A1
20060206201 Garcia et al. Sep 2006 A1
20060212127 Karabey et al. Sep 2006 A1
20060271149 Berez et al. Nov 2006 A1
20060271153 Garcia et al. Nov 2006 A1
20060276910 Weber Dec 2006 A1
20070021816 Rudin Jan 2007 A1
20070043419 Nikolchev et al. Feb 2007 A1
20070055365 Greenberg et al. Mar 2007 A1
20070060994 Gobran et al. Mar 2007 A1
20070073379 Chang Mar 2007 A1
20070077347 Richter Apr 2007 A1
20070100321 Rudakov et al. May 2007 A1
20070100414 Licata May 2007 A1
20070100430 Rudakov et al. May 2007 A1
20070112415 Bartlett May 2007 A1
20070119295 McCullagh May 2007 A1
20070123969 Gianotti May 2007 A1
20070162104 Frid Jul 2007 A1
20070167980 Figulla et al. Jul 2007 A1
20070198076 Hebert et al. Aug 2007 A1
20070203559 Freudenthal et al. Aug 2007 A1
20070203563 Hebert et al. Aug 2007 A1
20070208367 Fiorella et al. Sep 2007 A1
20070208373 Zaver et al. Sep 2007 A1
20070208376 Meng Sep 2007 A1
20070208415 Grotheim et al. Sep 2007 A1
20070219619 Dieck et al. Sep 2007 A1
20070225760 Moszner et al. Sep 2007 A1
20070233175 Zaver et al. Oct 2007 A1
20070239261 Bose et al. Oct 2007 A1
20070255386 Tenne Nov 2007 A1
20070255388 Rudakov et al. Nov 2007 A1
20070280850 Carlson Dec 2007 A1
20070299500 Hebert et al. Dec 2007 A1
20070299501 Hebert et al. Dec 2007 A1
20070299502 Hebert et al. Dec 2007 A1
20080015673 Chuter Jan 2008 A1
20080033341 Grad Feb 2008 A1
20080033526 Atladottir et al. Feb 2008 A1
20080039930 Jones et al. Feb 2008 A1
20080039933 Yodfat Feb 2008 A1
20080071351 Flanagan et al. Mar 2008 A1
20080082154 Tseng et al. Apr 2008 A1
20080114391 Dieck et al. May 2008 A1
20080119943 Armstrong et al. May 2008 A1
20080125855 Henkes et al. May 2008 A1
20080208320 Tan-Malecki et al. Aug 2008 A1
20080221666 Licata et al. Sep 2008 A1
20080221670 Clerc et al. Sep 2008 A1
20080221671 Chouinard et al. Sep 2008 A1
20080255654 Hebert et al. Oct 2008 A1
20080255655 Kusleika et al. Oct 2008 A1
20080262590 Murray Oct 2008 A1
20080269774 Garcia et al. Oct 2008 A1
20080275497 Palmer et al. Nov 2008 A1
20080275498 Palmer et al. Nov 2008 A1
20080294104 Mawad Nov 2008 A1
20080300667 Hebert et al. Dec 2008 A1
20080300668 Bonsignore Dec 2008 A1
20080300673 Clerc et al. Dec 2008 A1
20090024202 Dave et al. Jan 2009 A1
20090024205 Hebert et al. Jan 2009 A1
20090030496 Kaufmann Jan 2009 A1
20090030497 Metcalf et al. Jan 2009 A1
20090054981 Frid et al. Feb 2009 A1
20090099643 Hyodoh et al. Apr 2009 A1
20090105802 Henry et al. Apr 2009 A1
20090105803 Shelso Apr 2009 A1
20090125093 Hansen May 2009 A1
20090192536 Berez et al. Jul 2009 A1
20090192587 Frid Jul 2009 A1
20090198318 Berez et al. Aug 2009 A1
20090216307 Kaufmann et al. Aug 2009 A1
20090222035 Schneiderman Sep 2009 A1
20090270974 Berez et al. Oct 2009 A1
20090287241 Berez et al. Nov 2009 A1
20090287288 Berez et al. Nov 2009 A1
20090288000 McPherson Nov 2009 A1
20090292348 Berez et al. Nov 2009 A1
20090318947 Garcia et al. Dec 2009 A1
20090319017 Berez et al. Dec 2009 A1
20100010624 Berez et al. Jan 2010 A1
20100042200 Richter et al. Feb 2010 A1
20100061604 Nahm et al. Mar 2010 A1
20100063531 Rudakov et al. Mar 2010 A1
20100070024 Venturelli et al. Mar 2010 A1
20100076317 Babic et al. Mar 2010 A1
20100152834 Hannes et al. Jun 2010 A1
20100161025 Kuppurathanam et al. Jun 2010 A1
20100174269 Tompkins et al. Jul 2010 A1
20100174309 Fulkerson et al. Jul 2010 A1
20100179583 Carpenter et al. Jul 2010 A1
20100179647 Carpenter et al. Jul 2010 A1
20100198334 Yodfat et al. Aug 2010 A1
20100204779 Schuessler et al. Aug 2010 A1
20100211154 Murayama Aug 2010 A1
20100222864 Rivelli, Jr. et al. Sep 2010 A1
20100241214 Holzer et al. Sep 2010 A1
20100256732 Shin et al. Oct 2010 A1
20100256733 Schuessler Oct 2010 A1
20100280587 Ortiz et al. Nov 2010 A1
20100318174 Shaolian et al. Dec 2010 A1
20100318178 Rapaport et al. Dec 2010 A1
20110016427 Douen Jan 2011 A1
20110040372 Hansen et al. Feb 2011 A1
20110046718 Cattaneo Feb 2011 A1
20110046720 Shalev et al. Feb 2011 A1
20110054589 Bashiri et al. Mar 2011 A1
20110166592 Garcia et al. Jul 2011 A1
20110166637 Irwin et al. Jul 2011 A1
20110166639 Pulnev et al. Jul 2011 A1
20110179389 Douen Jul 2011 A1
20110184451 Sahl Jul 2011 A1
20110190862 Bashiri et al. Aug 2011 A1
20110245862 Dieck et al. Oct 2011 A1
20110270178 Fiorella et al. Nov 2011 A1
20120035643 Khairkhahan et al. Feb 2012 A1
20120041459 Fiorella et al. Feb 2012 A1
20120158124 Zaver et al. Jun 2012 A1
20120253454 Costello Oct 2012 A1
20120290067 Cam Nov 2012 A1
20120316638 Grad et al. Dec 2012 A1
20120323309 Cattaneo Dec 2012 A1
20130116773 Roeder et al. May 2013 A1
20130123901 Connor et al. May 2013 A1
20130138202 Paul et al. May 2013 A1
20130172975 Berez et al. Jul 2013 A1
20130190856 von Oepen et al. Jul 2013 A1
20130204347 Armstrong et al. Aug 2013 A1
20130211489 Makower et al. Aug 2013 A1
20130211497 Charlebois et al. Aug 2013 A1
20130274849 Zaver et al. Oct 2013 A1
20140018843 Berez et al. Jan 2014 A1
20140074149 Garcia et al. Mar 2014 A1
20140121744 Kusleika May 2014 A1
20140121745 Kusleika May 2014 A1
20140121746 Kusleika et al. May 2014 A1
20140128957 Losordo et al. May 2014 A1
20140222130 Kusleika Aug 2014 A1
20140316454 Zaver et al. Oct 2014 A1
20140336741 Connor et al. Nov 2014 A1
20150359646 Kusleika Dec 2015 A1
20170000631 Kusleika Jan 2017 A1
Foreign Referenced Citations (52)
Number Date Country
101472537 Jul 2009 CN
855170 Jul 1998 EP
1683541 Jul 2006 EP
1942972 Jul 2008 EP
1872742 May 2009 EP
2 078 512 Jul 2009 EP
2556210 Apr 1988 FR
10-328216 Dec 1998 JP
11-506686 Jun 1999 JP
11-299901 Nov 1999 JP
2001-509412 Jul 2001 JP
2002-253682 Sep 2002 JP
2003-520103 Jul 2003 JP
2004-049585 Feb 2004 JP
2005-074230 Mar 2005 JP
2006-506201 Feb 2006 JP
2008-502378 Jan 2008 JP
2008-541832 Nov 2008 JP
WO-8800813 Feb 1988 WO
WO-95009586 Apr 1995 WO
WO-95032757 Dec 1995 WO
WO-98004211 Feb 1998 WO
WO-9847447 Oct 1998 WO
WO-99002092 Jan 1999 WO
WO-9905977 Feb 1999 WO
WO-99049812 Dec 1999 WO
WO-01005331 Jan 2001 WO
WO-01052771 Jul 2001 WO
WO-02005729 Jan 2002 WO
WO-02047579 Jun 2002 WO
WO-02054988 Jan 2003 WO
WO-03007840 Jan 2003 WO
WO-03043527 May 2003 WO
WO-03049600 Jun 2003 WO
WO-03057079 Jul 2003 WO
WO-03073963 Sep 2003 WO
WO-2004087006 Nov 2004 WO
WO-2005021061 Mar 2005 WO
WO-2005023149 Dec 2005 WO
WO-2006034140 Mar 2006 WO
WO-2006073745 Jul 2006 WO
WO-2006127005 Nov 2006 WO
WO-2007122396 Nov 2007 WO
WO-20081005898 Jan 2008 WO
WO-2007139689 Sep 2008 WO
WO-2007139699 Sep 2008 WO
WO-2008156683 Dec 2008 WO
WO-2005115118 Jul 2009 WO
WO-2009105710 Aug 2009 WO
WO-2010127838 Nov 2010 WO
WO-2011023105 Mar 2011 WO
WO-2011134663 Nov 2011 WO
Non-Patent Literature Citations (16)
Entry
Benndorf, et al. Treatment of a Ruptured Dissecting Vertebral Artery Aneurysm with Double Stent Placement: Case Report AJNR Am J Neuroradiol, Nov.-Dec. 2001, vol. 22, pp. 1844-1848.
Brilstra, et al., Treatment of Intracranial Aneurysms by Embolization with Coils: A Systematic Review, Stroke, Journal of the American Heart Association, 1999, vol. 30, pp. 470-476.
Ferguson, Gary, Physical Factors in the Initiation, Growth and Rupture of Human Intracranial Saccular Aneurysms, J. Neurosurg, Dec. 1972, vol. 37, pp. 666-667.
Geremia, et al., Embolization of Experimentally Created Aneurysms with Intravascular Stent Devices, ANJR American Journal of Neuroradiology, Aug. 1994, vol. 15, pp. 1223-1231.
Geremia, et al., Occlusion of Experimentally Created Fusiform Aneurysms with Porous Metallic Stents, ANJR Am J Neuroradiol, Apr. 2000, Issue 21, pp. 739-745.
Lanzino, et al., Efficacy and Current Limitations of Intravascular Stents for Intracranial Internal Carotid, Vertebral, and Basilar Artery Aneurysms, Journal of Neurosurgery, Oct. 1999, vol. 91, Issue 4, pp. 538-546.
Lieber, et al., Alteration of Hemodynamics in Aneurysm Models by Stenting: Influence of Stent Porosity, Ann of Biomedical Eng., 1997, vol. 25, pp. 460-469, Buffalo, NY.
Lieber, et al., The Physics of Endoluminal Stenting in the Treatment of Cerebrovascular Aneurysms, Neurological Research, 2002, Vcol 24, Issue Supplement 1, pp. S32-S42.
Moss, et al., Vascular Occlusion with a Balloon-Expandable Stent Occluder, Radiology, May 1994, vol. 191, Issue 2, pp. 483-486.
Pereira, Edgard, History of Endovascular Aneurysm Occlusion, Management of Cerebral Aneurysms, 2004, pp. 11-26.
Qureshi, Adnan, Endovascular Treatment of Cerebrovascular Diseases and Intracranial Neoplasms, The Lancelet, Mar. 2004, vol. 363, pp. 804-81390.
Steiger, Pathophysiology of Development and Rupture of Cerebral Aneurysms, Acta Nurochirurgica, Mar. 1990, vol. Supplementum 48, Pages in 62 pages.
Tenaglia, et al., Ultrasound Guide Wire-Directed Stent Deployment, Duke University Medical Center, Department of Medicine, 1993 USA.
Yu, et al., A Steady Flow Analysis on the Stented and Non-Stented Sidewall Aneurysm Models, Medical Engineering and Physics, Apr. 1999, Issue 21, pp. 133-141.
U.S. Appl. No. 14/791,876, filed Jul. 6, 2015.
U.S. Appl. No. 14/714,619, filed May 18, 2015.
Related Publications (1)
Number Date Country
20150359646 A1 Dec 2015 US
Provisional Applications (1)
Number Date Country
61720154 Oct 2012 US
Continuations (1)
Number Date Country
Parent 13826971 Mar 2013 US
Child 14833768 US